# New clinical trials in Puerto Rico: 254 since Nov 2024

Updated November 5, 2026.

254 clinical studies with a site in Puerto Rico were first posted on ClinicalTrials.gov from November 18, 2024 to November 5, 2026; 223 have an industry sponsor and 182 are recruiting or about to. The newest, NCT07919405, was posted on November 5, 2026: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living... (Novo Nordisk A/S).

## The full list

New clinical trials with a site in Puerto Rico: 254 rows for $12.70, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/country/puerto-rico

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 254
- Industry sponsored: 223
- Recruiting or not yet: 182
- Latest posted: November 5, 2026

## Newest trials

The newest 100 of 254, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | Brazil, China, Germany, Japan, Puerto Rico, Romania, South Korea, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | Argentina, China, Germany, India, Japan, Puerto Rico, South Korea, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 9, 2026 | NCT07869043 | A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma | Pfizer | Phase 3 | Recruiting | Asthma | 1,100 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869043) |
| October 9, 2026 | NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 514 | China, Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867080) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| September 25, 2026 | NCT07840560 | Sleep Harmonization Via Bundled Team-Based Interventions in the ICU | University of California, San Diego | Not applicable | Not yet recruiting | Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium | 62,500 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840560) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | Argentina, Dominican Republic, Mexico, Panama, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| August 31, 2026 | NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1... | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal | 2,001 | Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794579) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | Argentina, Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 24, 2026 | NCT07782970 | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps... | GlaxoSmithKline | Phase 3 | Recruiting | Nasal Polyps | 218 | Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782970) |
| August 21, 2026 | NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early phase 1 | Not yet recruiting | MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma | 22 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778602) |
| August 20, 2026 | NCT07775300 | A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775300) |
| August 20, 2026 | NCT07775287 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent... | Genmab | Phase 3 | Recruiting | Colorectal Cancer | 600 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775287) |
| August 14, 2026 | NCT07765095 | Pericapsular Nerve Group (PENG) Block on Postoperative Pain Management After Acetabular Fracture Fixation | University of Puerto Rico | Not applicable | Recruiting | Acetabular Fractures | 56 | Puerto Rico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765095) |
| August 12, 2026 | NCT07759245 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Eli Lilly and Company | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 606 | Argentina, Austria, Canada, China, Czechia, Denmark, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759245) |
| August 10, 2026 | NCT07756645 | A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line... | AbbVie | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 940 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756645) |
| August 7, 2026 | NCT07752979 | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities | AbbVie | Phase 2 | Recruiting | Obesity, Overweight | 360 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752979) |
| August 5, 2026 | NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC)... | Hoffmann-La Roche | Phase 2 | Recruiting | Breast Cancer, Diabetes Type II | 40 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748208) |
| August 3, 2026 | NCT07742644 | A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Measles, Mumps, Rubella, Varicella (Chickenpox), Measles-Mumps-Rubella+Chickenpox Vaccine | 1,860 | Argentina, Finland, Italy, Puerto Rico, Taiwan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742644) |
| July 23, 2026 | NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With... | ORIC Pharmaceuticals | Phase 3 | Recruiting | Metastatic Castration Resistant Prostate Cancer | 600 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723248) |
| July 23, 2026 | NCT07722546 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old | Biogen | Phase 2 | Recruiting | Graves' Disease | 60 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722546) |
| July 17, 2026 | NCT07711002 | Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy... | AstraZeneca | Phase 3 | Recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 1,330 | Austria, Brazil, Canada, China, France, Germany, Hong Kong, Hungary, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711002) |
| July 16, 2026 | NCT07708727 | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment | Gilead Sciences | Phase 2/3 | Recruiting | HIV-1-infection | 700 | Canada, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708727) |
| July 14, 2026 | NCT07702032 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic... | Genmab | Phase 3 | Recruiting | Left-sided Colorectal Cancer | 960 | Australia, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702032) |
| July 6, 2026 | NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 3,200 | Australia, Canada, Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684235) |
| July 6, 2026 | NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Amgen | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 950 | Canada, Japan, Puerto Rico, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684144) |
| June 29, 2026 | NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | 570 | China, Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673887) |
| June 29, 2026 | NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer | Convergent Genomics, Inc. | Observational | Recruiting | Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer | 2,500 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673016) |
| June 23, 2026 | NCT07662109 | A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2... | AstraZeneca | Phase 3 | Recruiting | Type 2 Diabetes Mellitus | 2,000 | Argentina, Brazil, China, Czechia, Denmark, Germany, Greece, Hungary, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662109) |
| June 22, 2026 | NCT07661056 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | Biohaven Therapeutics Ltd. | Phase 3 | Recruiting | Graves Disease | 300 | Canada, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661056) |
| June 22, 2026 | NCT07660198 | Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents | Pfizer | Phase 3 | Recruiting | Pneumococcal Disease | 1,200 | Finland, Poland, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660198) |
| June 22, 2026 | NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Verastem, Inc. | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 105 | Australia, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659782) |
| June 18, 2026 | NCT07656727 | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk... | BioAge Labs, Inc. | Phase 2 | Active not recruiting | Obesity and Cardiovascular Risk | 160 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656727) |
| June 16, 2026 | NCT07650916 | A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With... | ViiV Healthcare | Phase 3 | Recruiting | HIV Infections | 564 | Argentina, Australia, Brazil, Canada, Japan, Mexico, Puerto Rico, Spain, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650916) |
| June 12, 2026 | NCT07645287 | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | Gilead Sciences | Phase 2 | Recruiting | HIV-1-infection | 175 | Australia, Canada, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645287) |
| June 12, 2026 | NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Verastem, Inc. | Phase 2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | 185 | Australia, Canada, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644559) |
| June 11, 2026 | NCT07641517 | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain | Eli Lilly and Company | Phase 2 | Recruiting | Osteoarthritis, Knee, Chronic Pain | 150 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641517) |
| June 11, 2026 | NCT07641504 | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain | Eli Lilly and Company | Phase 2 | Recruiting | Chronic Pain, Low Back Pain | 150 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641504) |
| June 10, 2026 | NCT07639268 | Caregivers-Patients Support to Cope With Advanced-Cancer (CASA) | Ponce Medical School Foundation, Inc. | Not applicable | Enrolling by invitation | Cancer (Advanced Stage), Caregivers, Patients, Stage III Cancer, Stage IV Cancer | 124 | Puerto Rico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639268) |
| June 10, 2026 | NCT07639021 | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Novo Nordisk A/S | Phase 2 | Active not recruiting | Obesity | 233 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639021) |
| June 8, 2026 | NCT07631637 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis, MASH | 360 | Puerto Rico, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631637) |
| June 5, 2026 | NCT07629440 | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. | Pfizer | Phase 3 | Recruiting | Pneumococcal Disease | 3,230 | Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629440) |
| May 28, 2026 | NCT07610837 | Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | AstraZeneca | Phase 2 | Recruiting | Liver Fibrosis, Hepatic Cirrhosis | 104 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610837) |
| May 27, 2026 | NCT07609719 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | Genentech, Inc. | Phase 4 | Recruiting | Multiple Sclerosis | 100 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609719) |
| May 22, 2026 | NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Eli Lilly and Company | Phase 3 | Recruiting | Alzheimer Disease, Dementia, Plaque, Amyloid | 550 | Japan, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602582) |
| May 18, 2026 | NCT07592273 | Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved... | AbbVie | Phase 2/3 | Recruiting | Diabetic Retinopathy | 576 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592273) |
| May 8, 2026 | NCT07575399 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in... | Amgen | Phase 3 | Recruiting | Obesity or Overweight | 300 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575399) |
| May 7, 2026 | NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | Revolution Medicines, Inc. | Not applicable | Approved for marketing | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer... | Not listed | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573215) |
| May 6, 2026 | NCT07571252 | Impact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery | University of Puerto Rico | Phase 4 | Recruiting | Post Operative Pain, Orthognathic Surgery | 72 | Puerto Rico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571252) |
| May 5, 2026 | NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Novo Nordisk A/S | Phase 3 | Recruiting | Obesity, Heart Failure | 5,610 | Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567001) |
| April 29, 2026 | NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple... | Hoffmann-La Roche | Phase 3 | Recruiting | Multiple Myeloma | 380 | Australia, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555938) |
| April 28, 2026 | NCT07553429 | A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated | Boehringer Ingelheim | Phase 1/2 | Recruiting | Diabetic Macular Edema | 49 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553429) |
| April 22, 2026 | NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian... | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 3 | Recruiting | Ovarian Cancer | 420 | Argentina, Australia, Belgium, Brazil, Canada, Croatia, Denmark, Estonia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546500) |
| April 13, 2026 | NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal... | Incyte Corporation | Phase 3 | Recruiting | Solid Tumors | 588 | Australia, Austria, Belgium, Canada, Denmark, Finland, France, Georgia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522073) |
| April 9, 2026 | NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | France, Netherlands, Puerto Rico, South Korea, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519655) |
| April 8, 2026 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen... | Novartis Pharmaceuticals | Phase 3 | Active not recruiting | Cardiovascular Disease and Lipoprotein(a) | 5,700 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517263) |
| April 3, 2026 | NCT07509307 | AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis... | Novo Nordisk A/S | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis, Knee | 400 | Australia, Bulgaria, Canada, Denmark, Greece, Italy, Poland, Puerto Rico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509307) |
| March 25, 2026 | NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not... | BeOne Medicines | Phase 3 | Recruiting | HR+/HER2- Breast Cancer | 1,056 | Australia, Brazil, China, France, Germany, Italy, Japan, Malaysia, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492641) |
| March 23, 2026 | NCT07489066 | Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC | Pfizer | Phase 2 | Recruiting | Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung... | 120 | Australia, China, Germany, Hong Kong, Israel, Italy, Poland, Puerto Rico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489066) |
| March 19, 2026 | NCT07484074 | A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 | Ollin Biosciences, Inc. | Phase 1 | Completed | Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration | 164 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484074) |
| March 4, 2026 | NCT07448714 | Animal Assisted Therapy | University of Puerto Rico | Not applicable | Completed | Dental Fear and Anxiety, Animal Assisted Therapy, Dental Treatment | 20 | Puerto Rico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448714) |
| March 2, 2026 | NCT07441642 | A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related... | Novartis Pharmaceuticals | Phase 2 | Recruiting | Geographic Atrophy Secondary to Age-related Macular Degeneration | 272 | Argentina, Australia, Brazil, Bulgaria, Canada, China, Colombia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441642) |
| February 27, 2026 | NCT07440225 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | EyeBiotech Ltd. | Phase 2/3 | Recruiting | Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration | 960 | Argentina, Australia, Estonia, Germany, Israel, Latvia, Poland, Puerto Rico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440225) |
| February 27, 2026 | NCT07437950 | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Acute Myeloid Leukemia | 126 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07437950) |
| February 24, 2026 | NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric... | AstraZeneca | Phase 3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431281) |
| February 20, 2026 | NCT07424404 | A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in... | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Schizophrenia, Autism-Related Irritability | 400 | Australia, Canada, France, Hungary, India, Japan, Poland, Puerto Rico, Romania... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424404) |
| February 19, 2026 | NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Pfizer | Phase 1/2 | Recruiting | Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma | 132 | Australia, China, Japan, Puerto Rico, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421700) |
| February 19, 2026 | NCT07420283 | A Study of Brenipatide in Participants With Opioid Use Disorder | Eli Lilly and Company | Phase 2 | Recruiting | Opioid Use Disorder | 465 | Canada, Puerto Rico, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420283) |
| February 17, 2026 | NCT07415044 | LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company | Phase 2 | Recruiting | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | 1,431 | Argentina, Brazil, Canada, China, Colombia, Croatia, Czechia, France, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415044) |
| February 17, 2026 | NCT07412756 | A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412756) |
| February 6, 2026 | NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Pfizer | Phase 2/3 | Recruiting | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric... | 840 | Canada, China, France, Israel, Italy, Japan, Puerto Rico, Spain, Taiwan, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392892) |
| February 6, 2026 | NCT07392190 | A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Obesity | 900 | Australia, Belgium, Brazil, China, Czechia, India, Israel, Japan, Mexico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392190) |
| February 6, 2026 | NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the... | National Cancer Institute (NCI) | Phase 3 | Recruiting | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer... | 1,978 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391774) |
| February 5, 2026 | NCT07388498 | A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via... | Amgen | Phase 3 | Recruiting | Uncontrolled Gout | 270 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388498) |
| January 27, 2026 | NCT07369102 | Esketamine With or Without Integration Therapy for Treatment-Resistant Depression | University of Puerto Rico | Phase 4 | Recruiting | Treatment-resistant Depression (TRD) | 20 | Puerto Rico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369102) |
| January 21, 2026 | NCT07353931 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Eli Lilly and Company | Phase 3 | Recruiting | Osteoarthritis, Overweight or Obesity | 900 | Argentina, Belgium, Canada, China, Czechia, Denmark, Germany, Japan, Puerto... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07353931) |
| January 20, 2026 | NCT07351058 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Type 2 Diabetes Mellitus | 1,600 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351058) |
| January 16, 2026 | NCT07348692 | Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | Sanofi | Phase 3 | Recruiting | Pneumococcal Immunization, Healthy Volunteers | 2,195 | Honduras, Puerto Rico, Thailand, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348692) |
| January 7, 2026 | NCT07321886 | A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight | 1,980 | Argentina, Australia, Belgium, Brazil, Canada, China, Germany, India, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321886) |
| December 29, 2025 | NCT07308158 | Covid Flu A/B and RSV 4 in 1 Diagnostic Test | iHealth Labs inc | Observational | Completed | Influenza A, Influenza B, COVID - 19, RSV | 1,119 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308158) |
| December 23, 2025 | NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis | 990 | Australia, Belgium, Bulgaria, Croatia, Czechia, Estonia, France, Georgia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299019) |
| December 16, 2025 | NCT07286175 | A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) | Eli Lilly and Company | Phase 2 | Recruiting | Bipolar Disorder | 400 | Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286175) |
| December 16, 2025 | NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Takeda | Phase 3 | Recruiting | Psoriatic Arthritis | 1,182 | Australia, China, Croatia, Czechia, Estonia, Germany, Hungary, Israel, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286058) |
| December 16, 2025 | NCT07285798 | A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Irritability Associated With Autism Spectrum Disorder | 176 | France, Germany, Hungary, India, Japan, Poland, Puerto Rico, Romania, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285798) |
| December 16, 2025 | NCT07285018 | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain | Eli Lilly and Company | Phase 2 | Recruiting | Diabetic Peripheral Neuropathic Pain | 150 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285018) |
| December 16, 2025 | NCT07284901 | Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Kailera | Phase 3 | Active not recruiting | Obesity With Diabetes, Overweight With Diabetes | 1,270 | Argentina, Australia, Bulgaria, Czechia, Germany, New Zealand, Poland, Puerto... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284901) |
| December 16, 2025 | NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line... | Incyte Corporation | Phase 3 | Recruiting | CRC (Colorectal Cancer) | 700 | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284849) |
| December 16, 2025 | NCT07284745 | A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Irritability Associated With Autism Spectrum Disorder | 176 | Australia, Canada, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284745) |
| December 16, 2025 | NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | Alliance for Clinical Trials in Oncology | Not applicable | Recruiting | Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon... | 420 | Guam, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283939) |
| December 15, 2025 | NCT07282600 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Obesity | 1,035 | China, Czechia, Germany, India, Japan, Mexico, Poland, Puerto Rico, Slovakia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282600) |
| December 11, 2025 | NCT07276581 | A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | AstraZeneca | Phase 2 | Recruiting | Rheumatoid Arthritis | 320 | Argentina, Brazil, Bulgaria, Canada, Chile, China, Germany, Hungary, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276581) |
| November 26, 2025 | NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)... | 500 | Canada, France, Germany, Italy, Japan, Puerto Rico, South Korea, Spain, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252232) |
| November 20, 2025 | NCT07238088 | Active Mammography and Counseling | University of Puerto Rico Comprehensive Cancer Center | Not applicable | Recruiting | Breast Cancer Prevention | 1,020 | Puerto Rico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238088) |
| November 17, 2025 | NCT07230834 | Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Geographic Atrophy (GA) | 54 | Georgia, Puerto Rico, Romania, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230834) |
| November 14, 2025 | NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Summit Therapeutics | Phase 3 | Recruiting | Metastatic Colorectal Cancer (CRC) | 900 | Belgium, Canada, China, Czechia, France, Germany, Hungary, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228832) |
| November 13, 2025 | NCT07227818 | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 560 | Puerto Rico, Serbia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227818) |
| November 12, 2025 | NCT07227298 | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced... | Pfizer | Phase 1/2 | Recruiting | Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer | 162 | China, France, Germany, Italy, Japan, Puerto Rico, Spain, Taiwan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227298) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Eli Lilly and Company | 35 | October 28, 2026 |
| Pfizer | 24 | October 9, 2026 |
| AbbVie | 13 | August 10, 2026 |
| Amgen | 9 | October 13, 2026 |
| AstraZeneca | 9 | July 17, 2026 |
| Bristol-Myers Squibb | 9 | December 16, 2025 |
| Hoffmann-La Roche | 8 | August 5, 2026 |
| University of Puerto Rico | 7 | August 14, 2026 |
| Novo Nordisk A/S | 6 | November 5, 2026 |
| Boehringer Ingelheim | 6 | April 28, 2026 |
| Novartis Pharmaceuticals | 6 | April 8, 2026 |
| Ponce Medical School Foundation, Inc. | 5 | June 10, 2026 |
| Sanofi | 5 | January 16, 2026 |
| GlaxoSmithKline | 4 | August 24, 2026 |
| Genmab | 4 | August 20, 2026 |
| Incyte Corporation | 4 | April 13, 2026 |
| BeOne Medicines | 4 | March 25, 2026 |
| National Cancer Institute (NCI) | 4 | February 27, 2026 |
| Merck Sharp & Dohme LLC | 4 | June 10, 2025 |
| Genentech, Inc. | 3 | May 27, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 35 | November 5, 2026 |
| [Overweight](https://specstream.ai/data/clinical-trials/condition/overweight) | 28 | October 28, 2026 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 14 | October 28, 2026 |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 12 | August 10, 2026 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 10 | August 20, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 7 | August 5, 2026 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 6 | November 5, 2026 |
| [Cardiovascular Diseases](https://specstream.ai/data/clinical-trials/condition/cardiovascular-diseases) | 6 | October 28, 2026 |
| [Atherosclerosis](https://specstream.ai/data/clinical-trials/condition/atherosclerosis) | 6 | August 25, 2026 |
| [Pancreatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms) | 6 | June 12, 2026 |
| [Alzheimer Disease](https://specstream.ai/data/clinical-trials/condition/alzheimer-disease) | 6 | May 22, 2026 |
| [Neoplasm Metastasis](https://specstream.ai/data/clinical-trials/condition/neoplasm-metastasis) | 6 | October 30, 2025 |
| [COVID-19](https://specstream.ai/data/clinical-trials/condition/covid-19) | 5 | September 9, 2026 |
| [Depression](https://specstream.ai/data/clinical-trials/condition/depression) | 5 | August 20, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 5 | April 9, 2026 |
| [Colonic Neoplasms](https://specstream.ai/data/clinical-trials/condition/colonic-neoplasms) | 5 | December 16, 2025 |
| Lung Diseases | 4 | August 12, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 4 | July 23, 2026 |
| [Recurrence](https://specstream.ai/data/clinical-trials/condition/recurrence) | 4 | July 23, 2026 |
| Pneumococcal Infections | 4 | June 22, 2026 |
| [Ovarian Neoplasms](https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms) | 4 | April 22, 2026 |
| [Esophageal Neoplasms](https://specstream.ai/data/clinical-trials/condition/esophageal-neoplasms) | 4 | April 9, 2026 |
| [Colitis, Ulcerative](https://specstream.ai/data/clinical-trials/condition/colitis-ulcerative) | 4 | February 17, 2026 |
| [Uterine Cervical Neoplasms](https://specstream.ai/data/clinical-trials/condition/uterine-cervical-neoplasms) | 4 | August 7, 2025 |
| Coronavirus Infections | 3 | September 9, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 141 | November 5, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 48 | September 9, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 22 | September 25, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 10 | April 9, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 9 | April 28, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 8 | July 16, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 8 | June 29, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 7 | May 27, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 1 | August 21, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).